ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last981 to 1,000 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Dietary Supplement/Vitamins vs Placebo for Vitamin C and Vitamin E: Maternal Death1 of 4,993

1 of 4,976

-0.0 points

-0.1 to 0.1

9,969NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Aspartate Aminotransferase ≥100 U/Liter35 of 4,993

48 of 4,976

-0.3 points

-0.6 to 0.1

9,969NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Severe or Mild Pregnancy-associated Hypertension With an Elevated Serum Creatinine Level7 of 4,993

11 of 4,976

-0.1 points

-0.3 to 0.1

9,969NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Severe or Mild Pregnancy-associated Hypertension With a Fetal Death After 20 Weeks of Gestation or Neonatal Death12 of 4,993

11 of 4,976

0.0 points

-0.2 to 0.2

9,969NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate305 of 4,993

285 of 4,976

0.4 points

-0.5 to 1.3

9,969NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Severe or Mild Pregnancy-associated Hypertension With an Eclamptic Seizure10 of 4,993

4 of 4,976

0.1 points

-0.0 to 0.3

9,969NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

VAX-MOM Intervention vs Standard of Care: Rate of Influenza Vaccination2,382 of 4,609

2,496 of 5,294

4.5 points

2.6 to 6.5

9,903NCT04444518

Increasing Influenza and Tdap Vaccination of Pregnant Women

Dulaglutide vs Placebo: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)594 of 4,949

663 of 4,952

-1.4 points

-2.7 to -0.1

9,901NCT01394952

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Dulaglutide vs Placebo: Number of Participants Who Experienced An Event for Time to First Occurrence After Randomization of Heart Failure Requiring Hospitalization or an Urgent Heart Failure Clinic Visit213 of 4,949

226 of 4,952

-0.3 points

-1.1 to 0.6

9,901NCT01394952

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Dulaglutide vs Placebo: Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of First Hospitalization for Unstable Angina88 of 4,949

77 of 4,952

0.2 points

-0.3 to 0.7

9,901NCT01394952

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Dulaglutide vs Placebo: Number of Participants Who Experienced an Event for Time to All-cause Mortality536 of 4,949

592 of 4,952

-1.1 points

-2.4 to 0.1

9,901NCT01394952

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Dulaglutide vs Placebo: Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of the Composite Microvascular Endpoint1,099 of 4,949

1,241 of 4,952

-2.9 points

-4.5 to -1.2

9,901NCT01394952

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Vitamins vs Placebo: Cesarean Delivery1,269 of 4,958

1,224 of 4,940

0.8 points

-0.9 to 2.5

9,898NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Intensive Protocol vs Usual Care Protocol: Mortality1,856 of 5,133

1,756 of 4,763

-0.7 points

-2.6 to 1.2

9,896NCT02933151

Health Effects of oraL Protein Supplements in HD (The HELPS-HD Trial)

Intensive Protocol vs Usual Care Protocol: deaths from any cause1,827 of 5,133

1,732 of 4,763

-0.8 points

-2.7 to 1.1

9,896NCT02933151

Health Effects of oraL Protein Supplements in HD (The HELPS-HD Trial)

Vitamins vs Placebo: Placental Abruption24 of 4,957

36 of 4,938

-0.2 points

-0.6 to 0.1

9,895NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Antepartum Bleeding56 of 4,956

46 of 4,937

0.2 points

-0.2 to 0.6

9,893NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Dulaglutide vs Placebo: deaths from any cause536 of 4,943

592 of 4,949

-1.1 points

-2.4 to 0.1

9,892NCT01394952

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Dulaglutide vs Placebo: serious adverse events1,991 of 4,943

2,044 of 4,949

-1.0 points

-3.0 to 0.9

9,892NCT01394952

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Vitamins vs Placebo: Medically Indicated Delivery Because of Hypertension509 of 4,952

473 of 4,934

0.7 points

-0.5 to 1.9

9,886NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=50

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00135707-ac3342e8",
        "title": "Dietary Supplement/Vitamins vs Placebo for Vitamin C and Vitamin E: Maternal Death",
        "summary": "1 of 4993 against 1 of 4976; risk difference -0.0 points, 95% interval -0.1 to 0.1; NCT00135707, Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)",
        "record": "/library/comparisons/NCT00135707-ac3342e8",
        "nct_id": "NCT00135707",
        "kind": "outcome",
        "participants": 9969,
        "risk_difference": {
          "value": -6.842376755109817e-7,
          "lower": -0.000951674786951715,
          "upper": 0.0009472671832005352
        },
        "group_1": "1 of 4,993",
        "group_2": "1 of 4,976",
        "difference": "-0.0 points",
        "interval": "-0.1 to 0.1",
        "trial_title": "Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)"
      },
      {
        "id": "NCT00135707-b98f96fd",
        "title": "Vitamins vs Placebo: Aspartate Aminotransferase ≥100 U/Liter",
        "summary": "35 of 4993 against 48 of 4976; risk difference -0.3 points, 95% interval -0.6 to 0.1; NCT00135707, Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)",
        "record": "/library/comparisons/NCT00135707-b98f96fd",
        "nct_id": "NCT00135707",
        "kind": "outcome",
        "participants": 9969,
        "risk_difference": {
          "value": -0.0026364885115689306,
          "lower": -0.006323052065825137,
          "upper": 0.000968694715300299
        },
        "group_1": "35 of 4,993",
        "group_2": "48 of 4,976",
        "difference": "-0.3 points",
        "interval": "-0.6 to 0.1",
        "trial_title": "Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=51",
  "request_id": "DInX_KEaB22k_dI1"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?